熱門資訊> 正文
Revolution Pharmaceuticals股价下跌5%，获得20亿美元灵活融资
2025-06-24 19:36
- A late-stage clinical oncology company, Revolution Medicines (NASDAQ:RVMD) partnered with Royalty Pharma on $2B in flexible funding to support its product development and commercialization for its portfolio of RAS inhibitors in the U.S. and internationally.
- The funding agreement provides for $2B in committed capital comprised of up to $1.25B in synthetic royalty monetization on sales of daraxonrasib, the company’s RAS(ON) multi-selective inhibitor, and up to $750M in corporate debt.
- The transaction expands the company's resources and optionality with $1.25B of the $2B available at the company's discretion.
- The stock price dropped 5.1% on Tuesday during pre-market hours of trading.
More on Revolution Medicines
- Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History
- Revolution Medicines, Inc. 2025 Q1 - Results - Earnings Call Presentation
- Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript
- Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib
- SA Asks: What are the best oncology stocks right now?
推薦文章
美股機會日報 | 估值8500億美元！傳OpenAI最新融資規模將破千億美元；黃仁勛稱將發佈幾款世界前所未見的新芯片
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
